首页> 外文OA文献 >Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

【2h】

Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

机译：与vorinostat（Suberoylanilide羟肟酸）的切肉（Suberoylanilide羟肟酸）增强达斯替尼（BMS-354825）的活性对伊马替尼甲磺酸盐敏感或伊马替尼酸脱糖胺慢性髓性白血病细胞

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Warren Fiskus; Michael Pranpat; Maria Balasis; Purva Bali; Veronica Estrella; Sandhya Kumaraswamy; Rekha Rao; Kathy Rocha; Bryan Herger; Francis Lee; Victoria Richon; Kapil Bhalla;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. [J] . Dai Y, Chen S, Venditti CA, Blood: The Journal of the American Society of Hematology . 2008,第3期

机译：在对甲磺酸伊马替尼敏感并具有耐药性的慢性粒细胞性白血病细胞中，伏立诺他能够协同增强MK-0457的致死性。
2. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, ab [J] . Rahmani M, Reese E, Dai Y, Molecular pharmacology. . 2005,第4期

机译：与辛二酰氨基苯胺异羟肟酸和17-烯丙基氨基17-去甲氧基格尔德霉素共同处理可协同诱导对STI571敏感和耐药的Bcr-Abl +细胞凋亡，并下调Bcr-Abl，ab
3. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. [J] . Tolomeo M, Grimaudo S, Di-Cristina A, Cancer letters . 2008,第2期

机译：高良姜精提高了对伊马替尼敏感和抗伊马替尼的Bcr-Abl表达白血病细胞中甲磺酸伊马替尼的细胞毒活性。
4. Proteomic Analysis of the Cytoskeleton Regulation in Chronic Myelogenous Leukemia Cells JURL-MK1: Effect of Imatinib Mesylate Treatment [C] . Petr Halada, Katerina Peslova, Dana Grebenova, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：慢性髓性白血病细胞Jull-MK1中细胞骨架调控的蛋白质组学分析：伊马替尼甲磺酸盐处理的影响
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Neoplasia: Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate [O] . Yun Dai, Shuang Chen, Charis A. Venditti, -1

机译：瘤形成：伏立诺他协同增效对甲磺酸伊马替尼敏感和耐药的慢性骨髓性白血病细胞中的MK-0457致死率
7. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate [O] . Dai, Yun, Chen, Shuang, Venditti, Charis A., 2008

机译：伏立诺他协同增强对甲磺酸伊马替尼敏感和耐药的慢性粒细胞白血病细胞中的MK-0457致死率
8. Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and -Refractory Bcr-Abl Expressing Leukemia [R] . Bhalla, K. 2008

机译：新型组蛋白去乙酰化酶和Bcr-abl抑制剂联合治疗伊马替尼甲磺酸盐敏感和难治性Bcr-abl表达白血病

Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

著录项

相似文献

相关主题

期刊订阅